Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis.


Journal

Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803

Informations de publication

Date de publication:
09 2019
Historique:
pubmed: 19 7 2019
medline: 11 3 2020
entrez: 19 7 2019
Statut: ppublish

Résumé

Objective Weibel-Palade bodies (WPBs) are endothelial cell (EC)-specific organelles formed by vWF (von Willebrand factor) polymerization and that contain the proangiogenic factor Ang-2 (angiopoietin-2). WPB exocytosis has been shown to be implicated for vascular repair and inflammatory responses. Here, we investigate the role of WPBs during angiogenesis and vessel stabilization. Approach and Results WPB density in ECs decreased at the angiogenic front of retinal vascular network during development and neovascularization compared with stable vessels. In vitro, VEGF (vascular endothelial growth factor) induced a VEGFR-2 (vascular endothelial growth factor receptor-2)-dependent exocytosis of WPBs that contain Ang-2 and consequently the secretion of vWF and Ang-2. Blocking VEGF-dependant WPB exocytosis and Ang-2 secretion promoted pericyte migration toward ECs. Pericyte migration was inhibited by adding recombinant Ang-2 or by silencing Ang-1 (angiopoietin-1) or Tie2 (angiopoietin-1 receptor) in pericytes. Consistently, in vivo anti-VEGF treatment induced accumulation of WPBs in retinal vessels because of the inhibition of WPB exocytosis and promoted the increase of pericyte coverage of retinal vessels during angiogenesis. In tumor angiogenesis, depletion of WPBs in vWF knockout tumor-bearing mice promoted an increase of tumor angiogenesis and a decrease of pericyte coverage of tumor vessels. By another approach, normalized tumor vessels had higher WPB density. Conclusions We demonstrate that WPB exocytosis and Ang-2 secretion are regulated during angiogenesis to limit pericyte coverage of remodeling vessels by disrupting Ang-1/Tie2 autocrine signaling in pericytes.

Identifiants

pubmed: 31315435
doi: 10.1161/ATVBAHA.119.313021
doi:

Substances chimiques

Angiopoietin-2 0
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1843-1858

Auteurs

Mélissande Cossutta (M)

From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.).

Marie Darche (M)

From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.).

Gilles Carpentier (G)

From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.).

Claire Houppe (C)

From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.).

Matteo Ponzo (M)

From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.).
Quinze Vingts National Ophthalmology Hospital, Paris, France (M.P.).

Fabio Raineri (F)

From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.).

Benoit Vallée (B)

From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.).

Maud-Emmanuelle Gilles (ME)

From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.).

Delphine Villain (D)

From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.).

Emilie Picard (E)

Inserm, U1138, Team 17, Physiopathology of Ocular Diseases to Clinical Development, University of Paris Descartes Sorbonne Paris Cité, Cordeliers Research Center, France (E.P.).

Caterina Casari (C)

Inserm, UMR S1176, Paris-Sud University, Paris-Saclay University, Le Kremlin-Bicêtre, France (C.C., C.D.).

Cécile Denis (C)

Inserm, UMR S1176, Paris-Sud University, Paris-Saclay University, Le Kremlin-Bicêtre, France (C.C., C.D.).

Michel Paques (M)

Department of Therapeutics, Sorbonne University, INSERM, CNRS, Vision Institute, Paris, France (M.P.).

José Courty (J)

From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.).

Ilaria Cascone (I)

From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH